SBIR/STTR Research Award

Novel Proteomic Arrays of In Vitro Expressed Proteins for Autoimmune Disease

Award identifier 226b988a5ebe09a8e27cf6f3efa1023d973f5d2248688c6e582f16ca3a71b2b6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$657,583

Program and phase

SBIR · Phase II

Award year

2007

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AMBERGEN, INC
Proposal award date
Not reported
Contract end date
Not reported
UEI
N9DGN6JJG5V5
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Progress in sequencing the human genome has led to a new goal - expressing and characterizing the human proteome. A promising area where proteomics can have a major impact is autoimmune disease. Proteome-wide screening against sera from patients with particular autoimmune diseases can enable the discovery of new autoantigens, the development of microarray-based diagnostic assays, and effective treatments for autoimmune disease. During Phase I, we developed a novel, low-cost, high throughput approach for proteomics based on Bead Sorted Libraries of In Vitro Expressed Proteins (BS-LIVE- PRO). These protein libraries can be expressed inexpensively in a single cell-free translation reaction using a Bead Sorted Library of In Vitro Expressible DNA (BS-LIVE-DNA) as a template. Additional novel technologies developed during Phase I which augment this approach include: i) solid-phase PCR to produce BS-LIVE-DNA from cDNA libraries, ii) a method (PC-PRINT) to rapidly phototransfer the protein on each bead in the BS-LIVE-PRO onto discrete spots on a microarray surface using proprietary photocleavable linkers, and iii) methods to decode the randomly arrayed spots generated by PC-PRINT using photo-transferable DNA or mass-tags (PC-CODE). We propose to extensively optimize and evaluate this new technology during Phase II with the aim of commercializing BS-LIVE-PRO. We will apply BS-LIVEPRO to autoimmune diseases in collaboration with Dr. Donald Bloch at the Massachusetts General Hospital, a leading expert on autoantigen discovery and primary biliary cirrhosis. Similar studies will be carried out on other vasculitis autoimmune diseases in association with Dr. Peter Merkel, Director of the Vasculitis Research Consortium. Proteome-wide screening against sera from patients with particular autoimmune diseases can lead to the discovery of new autoantigens, the development of diagnostic assays to identify autoimmune disease and, ultimately, improved treatments. We have developed a novel, low-cost, high throughput approach for proteomics based on Bead Sorted Libraries of In Vitro Expressed Proteins (BS-LIVE-PRO). We propose to extensively optimize and evaluate this new technology during Phase II with the aim of commercializing diagnostic assays for autoimmune diseases.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

56 SBIR/STTR records share this UEI (1995–2022). Reported award amounts total $41,142,314. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.